Clinical Trials Logo

Clinical Trial Summary

In recent years, with the maturity of laser technology, laser therapy is one of the popular options for the treatment of pigment diseases. The absorption spectrum of melanin ranges from 300 to 1,000 nm. In past studies, the 532 nm Q-switched Nd:YAG laser is effective for the treatment of superficial melanin. But there are still some side effects in laser treatment, such as post-inflammation pigmentation (PIH), depigmentation, skin redness, etc., and PIH is particularly likely to occur on darker skin. However, there is still no good evidence as to what factors or laser treatments can cause PIH. Therefore, in this study, we will use ApolloVue® S100 Image System (ApolloVue® S100 Image System is a medical device class II) to scan before and after skin of laser treatment to observe the changes in the skin condition. By observing and analyzing these changes, as a evaluation of predictors or prognostic factors after laser treatment and whether PIH will occur.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04861246
Study type Interventional
Source Taipei Veterans General Hospital, Taiwan
Contact Hsin Cheng, CRA
Phone +886-2-87523198
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date April 26, 2021
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT02891239 - 785nm Picosecond Laser for Treatment of Benign Pigmented Lesions N/A
Active, not recruiting NCT04208100 - Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands N/A
Completed NCT03409952 - Lutronic LaseMD for Treatment of Benign Pigmented Lesions N/A
Recruiting NCT02800525 - Comparison of Picosecond and Q-switched Laser for Benign Pigmented Lesions Treatment Phase 4
Completed NCT03774849 - PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles N/A
Completed NCT02146820 - Picosecond Laser for Ttreatment of Benign Pigmented Lesions N/A